Literature DB >> 15778068

Investigation of the release behavior of DEHP from infusion sets by paclitaxel-loaded polymeric micelles.

Sung Chul Kim1, Hye Jeong Yoon, Jang Won Lee, Jaewon Yu, Eun-Seok Park, Sang-Cheol Chi.   

Abstract

The current clinical formulation of paclitaxel (Taxol) contains 1:1 blend of Cremophor EL (polyethoxylated castor oil) and dehydrated ethanol. Cremophor EL and dehydrated ethanol are well known to leach di-(2-ethylhexyl) phthalate (DEHP) from polyvinyl chloride (PVC) infusion bags and PVC administration sets. DEHP is a possible hepatotoxin, carcinogen, teratogen and mutagen. Long-term exposure to DEHP may cause health risks. As an alternative formulation for paclitaxel, paclitaxel-loaded polymeric micelles (PLPM), made of monomethoxy poly(ethylene glycol)-block-poly(d,l-lactide) (mPEG-PDLLA) diblock copolymer, has demonstrated clear advantages over Taxol in pharmacokinetics and therapeutic index. Paclitaxel in either PLPM or Taxol formulations, diluted in 0.9% sodium chloride injection, was stable in the PVC infusion bags. The PLPM formulation significantly reduced the amount of DEHP extracted from PVC infusion bags and PVC administration sets. For PLPM diluted in 0.9% sodium chloride injection, the total amount of DEHP delivered over the simulated infusion period was 0.7 mg for 3h and 2.0 mg for 24 h, which was less than 2.9% of the DEHP extracted by Taxol. These results confirmed that there is negligible risk of DEHP exposure from diluted PLPM i.v. infusion using PVC infusion bags and PVC administration sets.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15778068     DOI: 10.1016/j.ijpharm.2005.01.011

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

1.  Extracorporeal tubing in the roller pump raceway: physical changes and particulate generation.

Authors:  Allison J Bednarski Spiwak; Alexander Horbal; Robert Leatherbury; Derek J Hansford
Journal:  J Extra Corpor Technol       Date:  2008-09

2.  Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.

Authors:  Jae-Lyun Lee; Jin-Hee Ahn; Se Hoon Park; Ho Young Lim; Jung Hye Kwon; Shin Ahn; Cheryn Song; Jun Hyuk Hong; Choung-Soo Kim; Hanjong Ahn
Journal:  Invest New Drugs       Date:  2011-10-20       Impact factor: 3.850

3.  Paclitaxel-conjugated PEG and arginine-grafted bioreducible poly (disulfide amine) micelles for co-delivery of drug and gene.

Authors:  Kihoon Nam; Hye Yeong Nam; Pyung-Hwan Kim; Sung Wan Kim
Journal:  Biomaterials       Date:  2012-08-04       Impact factor: 12.479

Review 4.  Polymeric Micelles: Recent Advancements in the Delivery of Anticancer Drugs.

Authors:  Avinash Gothwal; Iliyas Khan; Umesh Gupta
Journal:  Pharm Res       Date:  2015-09-17       Impact factor: 4.200

5.  Synthesis and characterization of low-toxicity N-caprinoyl-N-trimethyl chitosan as self-assembled micelles carriers for osthole.

Authors:  Xiao-juan Hu; Yang Liu; Xiao-feng Zhou; Qiao-ling Zhu; Yong-yan Bei; Ben-gang You; Chun-ge Zhang; Wei-liang Chen; Zhou-li Wang; Ai-jun Zhu; Xue-nong Zhang; Yu-jiang Fan
Journal:  Int J Nanomedicine       Date:  2013-09-20

6.  Injection device-related risk management toward safe administration of medications: experience in a university teaching hospital in The People's Republic of China.

Authors:  Ling-Ling Zhu; Wei Li; Ping Song; Quan Zhou
Journal:  Ther Clin Risk Manag       Date:  2014-03-17       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.